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Abstract 
Background: Glucose 6‑phosphate dehydrogenase (G6PD) is an enzyme involved in prevention of cellular oxida‑
tive damage, particularly protecting erythrocytes from haemolysis. An estimated 400 million people present variable 
degrees of inherited G6PD deficiency (G6PDd) which puts them at risk for developing haemolysis triggered by several 
risk factors including multiple drugs and certain foods. Primaquine (PQ) is a widely used anti‑malarial drug that can 
trigger haemolysis in individuals with G6PDd. Intensification of malaria control programmes worldwide and particu‑
larly malaria elimination planning in some regions recommend a more extensive use of PQ and related drugs in popu‑
lations with different G6PDd prevalence. This is a preliminary study to assess the prevalence of G6PDd in representa‑
tive malaria endemic areas of Colombia by measuring G6PD phonotype and genotypes.
Methods: Volunteers (n = 426) from four malaria endemic areas in Colombia (Buenaventura, Tumaco, Tierralta and 
Quibdo) were enrolled. Blood samples were drawn to evaluate G6PD enzymatic activity by using a quantitative G6PD 
test and a subset of samples was analysed by PCR–RFLP to determine the frequency of the three most common G6PD 
genotypic variants: A−, A+ and Mediterranean.
Results: A total of 28 individuals (6.56 %) displayed either severe or intermediate G6PDd. The highest prevalence 
(3.51 %) was in Buenaventura, whereas G6PDd prevalence was lower (<1 %) in Tierralta and Quibdo. G6PD A alleles 
were the most frequent (15.23 %) particularly in Buenaventura and Tumaco. Overall, a high frequency of G6PD A− 
genotype, followed by A+ genotype was found in the analysed population.
Conclusions: G6PDd based on enzymatic activity as well as G6PD A allelic variants were found in malaria‑endemic 
populations on the Pacific coast of Colombia, where most of malaria cases are caused by Plasmodium vivax infec‑
tions. These infections are treated for 14 days with PQ, however there are no official reports of PQ‑induced haemolytic 
crises. Further assessment of G6PDd prevalence in malaria endemic areas in Colombia is crucial in view of possible 
mass drug administration for malaria elimination in these regions, as well as implementation of appropriate G6PDd 
diagnostic methods.
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Background
Glucose 6-phosphate dehydrogenase (G6PD) is a cyto-
plasmic enzyme involved in prevention of cellular 
oxidative damage by stimulation of detoxification of free 
radicals. It catalyzes the production of nicotinamide ade-
nine dinucleotide phosphate (NADPH), which is neces-
sary for maintenance of reduced levels of glutathione 
(GSH) important to protect erythrocytes from oxidative 
damage and to reduce susceptibility to haemolysis [1, 
2]. However, globally more than 400 million people are 
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deficiency (G6PDd). G6PD deficient individuals, many 
of whom live in malaria endemic regions, are at risk of 
developing haemolytic crises triggered by several risk 
factors including multiple drugs and specific foods [3, 4].
The G6PD locus is located on chromosome X (Xq28) 
and displays a great polymorphism with  ~190 muta-
tions identified coding for  ~400 biochemical or allelic 
enzyme variants [5–7], some of which lead to functional 
deficiencies (G6PDd) that are transmitted as X-linked 
traits [8–10]. This transmission pattern results in G6PDd 
hemizygous males or homozygous females, whereas het-
erozygous females can be either normal or deficient in 
G6PD activity because of mosaicism [2].
Different prevalence of G6PDd has been reported in 
Africa (20 %), the Mediterranean (4–30 %) and Southeast 
Asia (10–20 %) [11]. In Latin America, where it has been 
less studied, prevalence ranges from  <2  % in countries 
such as Guatemala, Mexico and Peru to 16 % in Hondu-
ras [2, 12], including Venezuela with a prevalence of ~4 % 
[13]. The G6PDd African variants or “A” variants are 
among the most frequent worldwide, and the most com-
mon variants reported in the Americas. The A+ variant 
is characterized by one mutation from Adenine to Gua-
nine at position 376 in exon IV (376 A>G), exhibiting 
normal to very-mild deficiency (Class IV) whereas the 
A− variant (Class III) is the result from mutations in two 
positions in different exons: 376 A>G (exon IV) and 202 
G>A (exon V); it presents 8–20  % of normal enzymatic 
activity. The Mediterranean variant displays mutations in 
two positions in different exons including the A+ muta-
tion: 376 A>G (exon IV). Class II variant is produced by 
a change at position 563 in exon VI, corresponding to a 
transition from cytosine to thymine (563 C>T); it is con-
sidered a more severe variant, presenting with  <5  % of 
normal activity [14–16].
Primaquine (PQ), an 8-aminoquinoline, is cur-
rently considered the most effective drug to prevent 
Plasmodium vivax clinical relapses [17], as well as in 
Plasmodium falciparum infections to prevent gameto-
cyte development and further parasite transmission to 
mosquitoes [18]. However, PQ use has been restricted 
because it can trigger variable degrees of haemolysis in 
individuals with G6PDd, depending on the variant type. 
Due to intensification of malaria control programmes 
worldwide [19, 20] and the perspectives for malaria elim-
ination in some regions where PQ could be massively 
deployed, it is important to better characterize preva-
lence of G6PD in malaria endemic communities in these 
areas. In Colombia, previous studies have indicated a var-
iable G6PDd prevalence in certain regions according to 
phenotypic analyses: 12 and 12.7 % in Afro-descendants 
in Buenaventura and Cali, respectively, 3.1  % in a mes-
tizo population in Bogota, 2.2 % in mestizo, Amerindians 
and Afro-descendants in Medellin, and 14.8 % in healthy 
individuals and 9.5  % in malaria infected individuals in 
Turbo [21–25]. However, there is a lack of reports on 
haemolysis associated to PQ treatment in Colombia, 
even though  ~70  % of the malaria cases are caused by 
P. vivax and treated with PQ. According to the Colom-
bian guidelines for P. vivax malaria treatment, PQ must 
be administered for 14 days at a daily dose of 15 mg/day 
in combination with chloroquine (CQ) at a total dose of 
25 mg/kg; no PQ is currently used for treatment of P. fal-
ciparum infections [26]. This study aimed to determine 
the prevalence of both phenotypic and genotypic G6PDd 
in representative malaria endemic areas of Colombia 
located on the Pacific coast where P. vivax malaria is 
highly prevalent in endemic communities, many of which 
are of African descent. This is the first study including 
genotyping to evaluate locally important G6PDd vari-
ants in a large number of individuals from rural malaria 
endemic areas in the northwest of Colombia. Prelimi-
nary evaluation of both G6PD enzyme activity along with 
variant identification was important to study correlations 
between genotype and phenotype in these populations.
Methods
Ethics statement
Human blood samples were collected as part of a malaria 
epidemiology study in the context of an International 
Center of Excellence for Malaria Research (ICEMR) pro-
gramme. The protocol was reviewed and approved by the 
IRB of Malaria Vaccine and Drug Development Center-
MVDC (Cali-Colombia) (Code 004-2010). The screening 
process was considered to be of minimal risk according 
to resolution 8430 of 1993 of the Colombian Ministry of 
Health (MoH) [27]. Research was all performed in agree-
ment with the Declaration of Helsinki. Adults were asked 
to sign an informed consent (IC) form prior to inclusion, 
whereas children seven to 18 years old were asked to pro-
vide written informed assent (IA). For children <7 years 
old only the legal tutor was required to sign the IC for 
inclusion. Ethical clearance to draw blood samples was 
obtained by prior written IC, which was previously 
approved by the Ethical Committee of the MVDC IRB 
(CECIV) [28].
Study sites and population
This study was performed in four municipalities: Bue-
naventura (Valle del Cauca), Quibdo (Choco), Tierralta 
(department of Cordoba) and Tumaco (Nariño). These 
municipalities were selected based on the source of the 
malaria cases reported in the Colombian National Sur-
veillance System (SIVIGILA).
Buenaventura is a municipality located to the West 
of Colombia on the Pacific coast at 7 m above sea level 
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(m a s  l). It has a population of ~392,000 people (~85 % 
Afrocolombian,  ~10  % mestizos) [28]. A total of 334 
malaria cases (~71 % P. vivax) were reported by SIVIG-
ILA in 2014 [29], placing Buenaventura as a low risk zone 
(API = 0.8 cases/1000 inhabitants).
Quibdo is located to the northwest of Colombia at 
45  m  a  s  l. It has  ~160,000 inhabitants and most of 
them are Afrocolombian (~95  %). This municipality 
shows ~47 % of malaria cases caused by P. vivax, contrib-
uting 65 % of all malaria cases in Colombia according to 
SIVIGILA [29].
Tierralta is located to the northwest of Colombia, 
51  m  a  s  l and  ~50  km from the Colombian Atlantic 
coastline with a mean annual temperature of 27.3 °C [30]. 
Its population is an estimated ~97,000 inhabitants (~44 % 
living in rural areas) with 86  % mestizo, 8  % African-
American, and  ~2  % of native-American ethnicity [28]. 
Tierralta reported 844 malaria cases to SIVIGILA in 2014 
(~94.4 % P. vivax) [29] and is considered a moderate risk 
zone according to the Annual Parasite Index (API = 8.6 
cases/1000 inhabitants).
Tumaco is a municipality located to the southwest of 
Colombia on the Pacific coast at ~40 km from the bor-
der with Ecuador. It has a population of ~195,000 inhab-
itants [28]. It differs from the aforementioned localities 
in that P. falciparum is by far the most prevalent malaria 
pathogen. It reported 1309 malaria cases (1.1 % P. vivax, 
97.6 % P. falciparum and 0.3 % mixed infection) in 2014 
[29], which places it as a moderate risk zone (API = 6.7 
cases/1000 inhabitants).
Blood samples
Blood samples used here G6PD studies were randomly 
selected from a larger group of samples collected of 
healthy male and female donors of any age, randomly 
selected in cross sectional studies to determine malaria 
prevalence in sentinel sites of Buenaventura (n  =  118), 
Quibdo (n  =  100), Tierralta (n  =  119) and Tumaco 
(n = 89) [28]. Venous blood (4 mL for adults and 3 mL 
for children  <7  years) was collected by venipuncture 
into Vacutainer™ tubes (Becton-Dickinson) containing 
EDTA from a total of 426 volunteers who signed an IC 
or IA. Malaria infection was evaluated by microscopic 
and molecular examination. Enzyme activity assays for 
G6PD were performed using whole blood samples, and 
DNA was used to analyse G6PD allelic variants. After 
collection, samples were stored refrigerated at ~4 °C and 
G6PD activity assays were conducted within 7  days of 
collection.
Analysis of G6PD enzymatic activity in human blood
The G6PD activity was measured in all 426 volunteers. 
Initially, the haemoglobin (Hb) level was determined in 
all samples using 500  µL of whole blood and an auto-
mated haematology analyzer (KX-21 N, Sysmex, Roche). 
The G6PD activity was measured in 10 µL of whole blood 
samples using the quantitative G6PD kit from Trinity 
according to the manufacturer’s instructions (Trinity Bio-
tech, Ireland; Cat No 345-B) and was expressed in terms 
of Hb concentration. Normal, intermediate and deficient 
controls supplied by manufacturers were included in each 
determination. Enzyme activity was determined using a 
spectrophotometer (Biosystems, BTS 350) at 340 nm and 
it was reported as international units per gram of Hb(U/
gHb). The reference values for enzyme activity were: nor-
mal 4.6–13.5 U/gHb, intermediate deficiency 2.1–4.5 U/
gHb, and severe deficiency <2.1 U/gHb.
Molecular analysis to detect A+ , A− and Mediterranean 
variants
According to a previous estimation of 10 % prevalence 
of G6PDd in Colombia [2, 21], a subset of 123 samples 
were randomly selected to study the frequency of the 
three most common G6PD variants using PCR–RFLP. 
In addition, all samples with detected G6PDd were 
included in this analysis. First, PCR reactions were per-
formed to amplify exons IV, V and VI of the G6PD gene 
to characterize the genotypic variants A−, A+  and 
Mediterranean [31, 32]. DNA was extracted from blood 
samples using the PureLink™ Genomic DNA Mini Kit 
according to manufacturer’s recommendations (invit-
rogen™). All PCR reactions were performed to a final 
volume of 12.5  µL, using the GoTaq® Colorless Mas-
ter Mix according to manufacturer’s recommenda-
tions (Promega), 2  μL of DNA and specific primers 
for each region. The PCR conditions used to amplify 
the three fragments were: 94  °C/5  min, 35 cycles of 
95 °C/30 s, 62 °C/30 s, and 72 °C/30 s, and final exten-
sion of 72 °C/5 min for regions including mutations 376 
A>G (90  bp product) and 202 G>A (109  bp product). 
For the region including the mutation 563C-T (263 bp 
product) the PCR conditions for amplification were 
similar except for annealing and extension time which 
were 45  s. Finally, the PCR products were detected in 
3 % agarose gels. The PCR products were used in RFLP 
with specific restriction enzymes. All restriction reac-
tions were performed according to manufacturer’s 
recommendations. The mutation 376 A>G (G6PD 
A+  variant) was identified using the enzyme Fok I 
(New England Biolabs). The 202 G>A transition (G6PD 
A− variant) was detected by restriction with NIaIII 
(New England Biolabs). Finally, MobII (New England 
Biolabs) was used to detect the 563 C>T mutation asso-
ciated with the Mediterranean variant. The digested 
products were analysed through electrophoresis on 3 % 
agarose gels.
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Statistical analysis
Descriptive measures (mean, median, standard devia-
tion and range) and a Chi squared test were performed 
to describe and to test the relationship of variables such 
as age, gender, previous malaria infection, and number of 
previous malaria episodes, ethnicity and provenance with 
the presence of G6PDd (Tables  1, 2). A difference was 
considered significant if p value was <0.05. The EPIDAT 
(4.1 version) software and R were used to analyse data.
Results
A total of 426 volunteers, 251 females and 175 males, 
were screened for G6PD activity: 118 from Bue-
naventura, 100 from Quibdo, 119 from Tierralta and 89 
from Tumaco (Table  2). Eleven of the study volunteers 
presented malaria infection as determined by thick blood 
smear and PCR [28], but none of them showed G6PDd. 
No significant differences were found for G6PD activ-
ity among males and females. The average G6PD activ-
ity was 7.76 U/gHb, with 28 individuals (6.56 %; 7 males 
and 21 females) showing either severe or intermedi-
ate G6PDd reflected in values from 1.40 to 4.45 U/gHb 
(Fig.  1; Table  2). From these 28 patients, six (1.41  %; 2 
females and 4 males) showed severe G6PDd, whereas 22 
(5.15 %) showed intermediate deficiency. No differences 
were found between G6PDd and activity between males 
and females. There were regional differences in G6PD 
enzyme activity (p < 0.001) but no significant differences 
were detected in the prevalence of G6PDd. According 
to enzyme activity the highest prevalence was found in 
Buenaventura, where 15 (12.71  %) volunteers showed 
severe or intermediate deficiency followed by Tumaco, 
with seven G6PDd cases and the highest number of 
severe deficiency cases, four with severe deficiency and 
three with intermediate deficiency. Tierralta and Quibdo, 
showed the lowest prevalence of G6PDd with only inter-
mediate deficiency (Table 2).
None of the patients with G6PDd had severe anaemia 
(Hb <7 g/dL) (Table 2 and Fig. 2). Five individuals (four 
males and one female) with severe G6PDd showed nor-
mal levels of Hb (>12  g/dL in females and  >13  g/dL in 
males). However, seven volunteers had mild to moderate 
anaemia, one female with severe deficiency (7.0–11.9 g/
dL in females and 7.0–12.9  g/dL in males), and six vol-
unteers (five females and one male) with intermediate 
G6PDd (Fig. 2).
Analysis of G6PD allelic variants by PCR–RFLP was 
successful for 151 samples, 77 (50.99  %) female and 74 
(49.01  %) male individuals, including 123 patients with 
normal G6PD activity, 22 with intermediate deficiency 
and six that showed severe deficiency. A total of 23 indi-
viduals (15.23  %) showed genotypes associated with 
Table 1 Demographic characteristics of  selected people and  frequency of  people with  previous malaria episodes 
by G6PDd classification
Area Ethnicity n (%) Severe Intermediate Normal Overproduction
Buenaventura Afrocolombian 94 2 12 78 2
Mestizo 4 0 1 3 0
Other 20 0 0 20 0
Total 118 2 13 101 2
Quibdo Afrocolombian 86 0 1 85 0
Mestizo 4 0 0 4 0
Other 10 0 1 9 0
Total 100 0 2 98 0
Tierralta Afrocolombian 2 0 0 2 0
Mestizo 94 0 3 88 3
Other 23 0 1 21 1
Total 119 0 4 111 4
Tumaco Afrocolombian 44 2 1 40 1
Mestizo 11 0 1 10 0
Other 34 2 1 30 1
Total 89 4 3 80 2
Previous malaria episodes
 No 147 1 4 139 3
 Yes 279 5 18 251 5
Total 426 6 22 390 8
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Table 2 Prevalence of G6PDd and summary statistics for G6PD enzyme activity and haemoglobin values for gender clas-
sification and areas of study






Hb (g/dL) G6PD  
(U/gHb)
Hb (g/dL) G6PD  
(U/gHb)




 Male 175 1.40 7.10 7.51 12.90 7.72 12.99 23.8 23.00 7 (4.00) [1.76, 8.39]




118 1.70 7.10 7.38 12.00 7.34 12.26 23.80 19.70 15 (12.71) [7.53, 20.41]
 Tierralta 119 2.61 9.00 8.42 12.40 8.50 12.67 15.80 23.00 4 (3.36) [1.08, 8.90]
 Tumaco 89 1.40 7.40 8.30 12.70 8.04 12.51 15.50 18.00 7 (7.87) [3.49, 16.05]
 Quibdo 100 4.17 9.00 6.64 12.20 7.11 12.61 12.65 17.70 2 (2.00) [0.35, 7.74]
Total 426 1.40 7.10 7.76 12.30 7.76 12.51 23.80 23.00 28 (6.56) [4.49, 9.47]
Fig. 1 Geographic distribution of G6PD deficiency according to enzyme activity. G6PDd according to levels of enzymatic activity is shown in pie 
charts for each of the four regions in Colombia included in this study, all located on the coast. Average levels including all regions are shown in the 
lower right pie chart
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G6PD deficiency (Table 3). Only the G6PD genotypes A− 
or A+ were found. In contrast, no Mediterranean variant 
was identified. The G6PD A− variant (376 A>G and 202 
G>A mutations) was identified in 10 (6.62 %) hemizygous 
males and seven (4.64 %) females (four heterozygous and 
three homozygous). The A+ variant, which only includes 
the 376 A>G mutation, was found in five (3.31 %) hemizy-
gous males, and only one heterozygous female (Table 3). 
The remaining 128 individuals did not show any of the 
mutations evaluated in this study. The highest proportion 
of individuals with G6PD A− and A+ variants was found 
in Tumaco (26.67 %) and Buenaventura (24.39 %). How-
ever, the number of individuals characterized in Tumaco 
was the lowest among all municipalities (Table  4). The 
lowest frequency of these two G6PD variants was identi-
fied in Tierralta (5.00 %) and Quibdo (7.50 %) (Table 4). 
The geographic distribution of all variants in this study is 
summarized in Fig. 3.
The enzymatic activity and molecular characteriza-
tion were compared to evaluate the association between 
G6PD variants and enzyme deficiency. Eight of 28 indi-
viduals with enzymatic deficiency showed one of the 
G6PD allelic variants analysed in this study, whereas the 
remaining 20 individuals were wild type for the three var-
iants (Table 3). Two individuals from Buenaventura with 
intermediate enzymatic deficiency showed the G6PD 
A+  and G6PD A− variants respectively. Additionally, 
in this same municipality, one male with the A− variant 
showed severe deficiency (Table  4). Similarly, in Tier-
ralta two individuals with A+  and A− variants showed 
intermediate G6PDd (Table  4). Finally, three individu-
als with the G6PD A− variant in Tumaco showed severe 
deficiency (Table  4). In this study, the G6PD A− allelic 
variant was found associated with both severe and inter-
mediate deficiency, whereas the A+  genotype was only 
associated with intermediate deficiency (Table  4). The 
remaining 15 individuals with G6PD A allelic variants 
showed normal activity.
Discussion
This is the first study performed to evaluate the preva-
lence of G6PDd in a large number of individuals through 
enzymatic activity accompanied by genotyping analysis in 
malaria endemic regions on the Pacific coast in Colom-
bia. This approach allowed to preliminarily evaluate the 
frequency of allelic variants associated with G6PDd in 
municipalities from this region of Colombia.
This study found 6.56 % of analysed individuals show-
ing G6PD deficient activity including both interme-
diate and severe deficiency. This overall frequency is 
lower than the 10  % prevalence reported previously for 
Fig. 2 Level of G6PD activity and Haemoglobin. Hb concentra‑
tion >12 g/dL in females and >13 g/dL in males were considered 
normal, between 7.0 and 11.9 g/dL mild to moderate anaemia, 
and <7.0 g/dL corresponded to severely low or severe anaemia
Table 3 Number of  G6PD alleles among  individuals 
according to gender









Wild type  
n (%)
Gender
 Male 67 (44.3) 5 (3.31) 4 (2.65) 58 (38.41)
 Female 56 (37.09) 6 (3.97) 0 (0.00) 50 (33.11)
Deficiency
 Intermediate 22 (14.57) 2 (1.32) 2 (1.32) 18 (11.92)
 Severe 6 (3.97) 4 (2.65) 0 (0.00) 2 (1.32)
Total 151 (100) 17 (11.26) 6 (3.97) 128 (84.77)
Table 4 Proportion of G6PD genotypes by municipalities






n (%) Confidence 
intervals
Buenaventura 41 A− 6 (14.63) [6.09, 29.86]
A+ 4 (9.76) [3.17, 24.06]
Wild type 31 (75.61) [59.36, 97.09]
Quibdo 40 A− 3 (7.50) [1.96, 21.48]
A+ 0 (0.00) [0.00, 10.91]
Wild type 37 (92.50) [78.52, 98.04]
Tierralta 40 A− 1 (2.50) [0.13, 14.73]
A+ 1 (2.50) [0.13, 14.73]
Wild type 38 (95.00) [81.79, 99.13]
Tumaco 30 A− 7 (23.33) [10.64, 42.70]
A+ 1 (3.33) [0.17, 19.05]
Wild type 22 (73.33) [53.83, 87.02]
Total 151 A− 17 (11.26) [6.89, 17.67]
A+ 6 (3.97) [1.63, 8.83]
Wild type 128 (84.77) [77.81, 89.90]
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Colombia in a recent review which includes studies from 
Latin America [2, 21], the 12 % reported in Buenaventura 
for 242 individuals [21], 14.7  % in 508 individuals in 
Turbo [25] and the 12.7  % found in Cali [23]. However, 
the results found in this study were higher than previous 
reports including a G6PDd prevalence of 3.1 % in a mes-
tizo population in Bogotá [22] and 2.2 % in 500 Amerin-
dians and Afro-Amerindians individuals in Medellin [25]. 
The differences in G6PD activity found in various Colom-
bian studies are probably due to composition of the dif-
ferent populations evaluated; a higher G6PDd prevalence 
in Afro-descendants is likely, particularly in malaria 
endemic regions.
The A− and A+  allelic variants are the most often 
reported globally associated with G6PDd, although 
the A− variant is the one most frequently evaluated 
in G6PDd studies in populations of African descent. In 
this study, 15.23 % of the individuals had G6PD A geno-
types, mostly A− (11.26 % A− and 3.97 % A+), which is 
in agreement with a previous study showing that A− was 
the predominant G6PDd allelic variant in some countries 
in Latin America and the Caribbean [2]. Furthermore, the 
frequency of the G6PD A genotypes found in this study 
was similar to a recent study performed in Honduras that 
detected 11.81  % of individuals with A−  genotype and 
4.27 % for A+ [12]. These similarities are probably due to 
the population structure evaluated in these two studies, 
mainly Afro-descendants located in coastal regions. In 
contrast, the frequency of G6PD A− genotype found in 
a study performed in Venezuela was lower (2.56 %) [13].
Tumaco (26.66 %) and Buenaventura (24.39 %) showed 
the highest allelic G6PDd frequencies (Fig.  3). The 
population of these two municipalities is mainly Afro-
descendants (~90  %). Interestingly, these municipalities 
Fig. 3 Geographic distribution of G6PD allelic variants identified on the Colombian Pacific coast. G6PD genotypes wild‑type, A− and A+ are shown 
in pie charts for each of the four regions in Colombia included in this study. Average levels including all regions are shown in the lower right pie chart
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are malaria endemic sites in Colombia with a predomi-
nance of P. vivax malaria infections. The lowest propor-
tion of individuals with G6PDd variants was found in 
Quibdo.
When the enzymatic activity was evaluated, a greater 
proportion of G6PD deficient females compared to 
deficient males was found. However, from genotyp-
ing analysis, the proportion of hemizygous males with 
G6PDd variants was higher than females (heterozygous 
or homozygous). In Honduras, a greater proportion of 
females with G6PDd allelic variants were reported com-
pared to hemizygous males [12].
In some individuals it was founded G6PDd probably 
associated with the presence of A + and A− genotypes. 
A significant association between deficient enzyme activ-
ity and the presence of G6PDd genetic variants was 
found (p  =  0.04098). Eight individuals presented func-
tional G6PDd and displayed the corresponding genetic 
variants, however, these variants were not detected in 
the remaining 20 individuals that showed reduced G6PD 
enzyme activity. A plausible explanation is that G6PDd 
in these individuals is probably associated with other 
variants not evaluated in this study, which have not been 
characterized for the Colombian population and could be 
identified in the future by DNA sequencing of all exons.
This is the first report regarding frequency of G6PDd 
allelic variants in regions with endemic P. vivax malaria 
on the Colombian Pacific coast. Additionally, this study 
shows an important association between genotype and 
phenotype in these regions. Previous studies did not 
report allelic variants in individuals with reduced G6PD 
activity [22]. Here the A− genotype was detected in most 
of the samples with severe G6PDd (Table 3). It is surpris-
ing that no reports on haemolysis associated with the use 
of PQ use are available from these regions despite its fre-
quent use and apparent good treatment compliance.
Used for treatment of both P. falciparum (the majority 
of malaria cases in Africa) and P. vivax (70 % of malaria 
cases in Colombia) PQ is important for elimination 
of liver hypnozoites in P. vivax malaria. The PQ regi-
men for P. vivax malaria consists of a much higher dose 
than the currently recommended WHO single low dose 
(0.25  mg  base/kg) to block P. falciparum malaria trans-
mission which is associated with a considerably lower 
risk of haemolytic toxicity [3]. Acute haemolytic anaemia 
(AHA) is the most common complication triggered by 
PQ in G6PD deficient-individuals in Latin America and 
the Caribbean region [2]. A recent report showed that 
G6PD A− was the allelic variant present in autopsy tis-
sue samples from a previously reported death in the Bra-
zilian Amazon due to PQ treatment of P. vivax malaria 
[33, 34]. Therefore, in Latin American countries such as 
Colombia and Brazil where P. vivax is the main parasite 
causing malaria, it is recommended that PQ administra-
tion requires prior determination of G6PD status (nor-
mal or deficient). However, this recommendation is not 
followed in most endemic countries of the continent, and 
it is uncertain what proportion of malaria cases, mainly 
P. vivax that are treated with therapeutic protocols 
including PQ, develop haemolysis. Substantial reduc-
tion of malaria by implementation of mass drug admin-
istration (MDA) using PQ has been observed in regions 
with high prevalence of P. vivax and varying prevalence 
of G6PDd [35]. The particularly high prevalence of 
sub-microscopic infections in Colombia [28] must be 
considered by malaria control programmes. The imple-
mentation of MDA through mass PQ prophylactic treat-
ment (MPPT) [36], including sub-microscopic carriers, is 
possibly an important approach to reduction of transmis-
sion in Colombia. Such implementation would benefit 
from development of a suitable method for diagnosis of 
G6PDd in these locations. Testing for G6PDd is currently 
limited by cost, infrastructure, and logistics.
This study offered estimates of G6PDd prevalence in 
malaria endemic areas with considerable populations of 
African descent in a relatively small sample, a limitation 
of our study. Importantly, genotyping for the first time 
in these regions showed a high proportion of the G6PD 
A− variant in these populations. However, more infor-
mation is needed about G6PDd prevalence in malaria 
endemic areas in Colombia, and other endemic coun-
tries of the Latin American region, including additional 
variants not evaluated in this study that may be associ-
ated with G6PDd in 20 individuals with no identified 
G6PD alleles. Further mapping of G6PDd prevalence and 
variants will help design appropriate malaria elimination 
strategies including MDA with PQ. A prospective study 
with a larger sample size including a close follow up to 
detect potential development of haemolysis and haemo-
lytic anaemia in P. vivax patients under PQ treatment 
was recently initiated in collaboration with the MoH of 
Colombia. The MoH is currently preparing pilot activi-
ties towards malaria elimination which include the intro-
duction of PQ treatment for P. falciparum cases, and 
more intensive search and treatment of asymptomatic 
cases, which are mostly P. vivax cases demanding 2 week 
PQ regimens.
Conclusions
A high frequency of G6PD A− genotype, followed by 
A+  genotype was found in the analysed population, 
along with a moderately high proportion (6.56  %) of 
G6PDd based on enzymatic activity. Although 70  % of 
national malaria cases correspond to P. vivax infections 
and are treated for 14 days with PQ, no official reports of 
PQ-induced haemolytic crises are available. These results 
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underscore the need to more carefully assess G6PDd in 
malaria endemic populations, certainly in a larger popu-
lation, including other variants and sequencing as well as 
clinical follow up of PQ response. This study emphasizes 
the need to implement appropriate G6PDd diagnostic 
methods, particularly in view of possible MDA with PQ 
for both P. vivax and P. falciparum elimination.
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